If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
683.00    101.00 (17.35%)
Bid:
680.00
Ask:
684.00
Spread: 4.00 (0.588%)
Market Cap: £595.06m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

Today 07:00

RNS Number : 2212L
Victrex PLC
07 July 2026
 

7 July 2026

Victrex plc - Q3 trading update

'Momentum continues in Q3: full year guidance maintained'

Victrex plc is an innovative world leader in high performance polymer solutions, focused on the end markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Today's trading update covers the third quarter (Q3) of FY 2026, from 1 April 2026 to 30 June 2026.

 

Q3 and year-to-date (YTD) performance summary

 

·

Q3 (3 months ended 30 June 2026) Group revenues grew 18% vs Q3 2025, driven by Group volumes increasing by 17%. Year-on-year performance reflects momentum continuing from Q2 in Sustainable Solutions end markets, supported by some stabilisation in Medical.

·

At divisional level, Aerospace and Electronics were the main drivers of growth in Sustainable Solutions. Aerospace had a much weaker prior year comparator following industry supply chain backlogs in 2025.

·

Average selling price (ASP) of £68/kg was in line with the prior year (Q3 2025: £68/kg).

·

Year to date (YTD) Group revenues increased by 7%, with YTD Group volumes up 10%.

 

 

Quarter ended 30 June

 (Q3)

Nine months ended 30 June

(YTD)

2026

 

2025

% change

 

2026 2025 % change

Revenue (£m)

84.5

71.5

+18%

231.6 217.3 +7%

Sales volume (tonnes)

1,238

1,057

+17%

3,375 3,075 +10%

 

Good progress with Profit Improvement Plan and Unlocking Victrex's Potential

Since the start of 2026, we have made good progress in taking actions to simplify the business, to refresh our leadership team and decentralise our organisation, enabling us to become closer to our customers. Our headcount reduction of c10% of roles will start to see initial benefits in our final quarter (Q4), with most employees directly affected having left the business during Q3. We remain on track for annualised cost savings of at least £10m, which will be fully realised in FY 2027. As previously communicated, cash exceptional items for FY 2026 are expected to be approximately £10m.

 

Financial position

Net debt at 30 June 2026 was £43.0m, with cash of £27.5m. This is after payment of the Group's FY 2026 interim dividend (13.42p/share), totalling approximately £12m.

 

Outlook: full-year guidance maintained

 

Dr James Routh, Chief Executive Officer of Victrex, said:

 

"Q3 maintained the positive momentum we saw through our second quarter. Compared to the prior year, revenue growth was driven by improvement across several end markets, particularly Aerospace and Electronics, with some stabilisation in Medical.

 

In our final quarter (Q4), whilst we will start to see initial cost savings as part of our Profit Improvement Plan, we remain mindful of normal seasonality and wider macroeconomic conditions including the potential implications for global demand and energy costs. Our full year guidance is therefore unchanged and as previously communicated, the Board expects FY 2026 underlying PBT to be in the range of £42m-£44m.

 

Our growth opportunities remain strong across a broad range of end markets and geographies. With a clear and differentiated value proposition, unmatched expertise in PEEK and world class applications know-how, we are focused on driving significant improvement in profitability over the medium term."

 

Capital Markets Event 2026: Unlocking Victrex's Potential

 

The Group will host its 2026 Capital Markets Event 'Unlocking Victrex's Potential' at Investec, 30 Gresham Street, London, EC2V 7QP, UK, on Thursday 24th September starting at 15.00 UK time, followed by an informal reception at 18.00.

 

This event will focus on:

· Progress in our Profit Improvement Plan

· The addressable market and delivering new application opportunities for VictrexTM PEEK

· Our revised operating model and refreshed leadership team

· Our roadmap to significant improvement in profitability over the medium term

 

Victrex plc:

 

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG 

+44 (0) 7809 595831

Ian Melling, Chief Financial Officer

+44 (0) 1253 897700

Dr James Routh, Chief Executive Officer

+44 (0) 1253 897700

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the end-markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to energy operations and medical devices. With over 40 years' experience, our products shape future performance for our customers and our end-markets, enable environmental and societal benefit and drive value for our shareholders. Find out more at www.victrexplc.com

 

Forward looking statements:

This announcement has been prepared solely to provide additional information to the shareholders of Victrex plc, to meet the requirements of the FCA's Disclosure and Transparency Rules. It should not be relied on by any other party, for any other purposes. Forward-looking statements have been made by the directors in good faith, using information available up until the date on which they approved this statement. Forward-looking statements should be regarded with caution, because of the inherent uncertainties in economic trends and business risks.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUGPMUPQGQQ
Date   Source Headline
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.